Abstract
BACKGROUND Sporadic Alzheimer’s disease (sAD) is not a global brain disease. Specific regions, layers and neurons degenerate early while others remain untouched even in advanced disease. The prevailing model used to explain this selective neurodegeneration—prion-like Tau spread—has key limitations and is not easily integrated with other defining sAD features. Instead, we propose that in humans Tau hyperphosphorylation occurs locally via disruption in ApoER2-Dab1 signaling and thus the presence of ApoER2 in neuronal membranes confers vulnerability to degeneration. Further, we propose that disruption of the Reelin/ApoE/ApoJ-ApoER2-Dab1 P85α-LIMK1-Tau-PSD95 (RAAAD-P-LTP) pathway induces deficits in memory and cognition by impeding neuronal lipoprotein internalization and destabilizing actin, microtubules, and synapses. This new model is based in part on our recent finding that ApoER2-Dab1 disruption is evident in entorhinal-hippocampal terminal zones in sAD. Here, we hypothesized that neurons that degenerate in the earliest stages of sAD (1) strongly express ApoER2 and (2) show evidence of ApoER2-Dab1 disruption through co-accumulation of multiple RAAAD-P-LTP components.
METHODS We applied in situ hybridization and immunohistochemistry to characterize ApoER2 expression and accumulation of RAAAD-P-LTP components in five regions that are prone to early pTau pathology in 64 rapidly autopsied cases spanning the clinicopathological spectrum of sAD.
RESULTS We found that: (1) selectively vulnerable neuron populations strongly express ApoER2; (2) numerous RAAAD P-LTP pathway components accumulate in neuritic plaques and abnormal neurons; and (3) RAAAD-P-LTP components were higher in MCI and sAD cases and correlated with histological progression and cognitive deficits. Multiplex-IHC revealed that Dab1, pP85αTyr607, pLIMK1Thr508, pTau and pPSD95Thr19 accumulated together within dystrophic dendrites and soma of ApoER2-expressing neurons in the vicinity of ApoE/ApoJ enriched extracellular plaques. These observations provide evidence for molecular derangements that can be traced back to ApoER2-Dab1 disruption, in each of the sampled regions, layers, and neuron populations that are prone to early pTau pathology.
CONCLUSION Findings support the RAAAD-P-LTP hypothesis, a unifying model that implicates dendritic ApoER2-Dab1 disruption as the major driver of both pTau accumulation and neurodegeneration in sAD. This model provides a new conceptual framework to explain why specific neurons degenerate and identifies RAAAD-P-LTP pathway components as potential mechanism-based biomarkers and therapeutic targets for sAD.
Competing Interest Statement
The National Institutes of Health has filed patent applications related to mechanism-based biomarkers that are broadly related to this manuscript, with one coauthor (CER) named as an inventor.
Funding Statement
This project was supported by the intramural programs of NIA, NIAAA and NINDS, NIH. Additional support was provided as a research gift from John M. Davis to the Laboratory of Clinical Investigation, NIA/NIH. The MP-IHC work utilized the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). We are grateful to the research volunteers and the UA-HBB, BBDP, and UK-ADRC research teams including Henry Waldvogel, Clinton Turner and Marika Ezses (UA-HBB) and Geidy Serrano (BBDP). The UA-HBB is supported by the Neurological Foundation of New Zealand. The BBDP is supported by the NINDS (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the NIA (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. The UK-ADRC is supported by the NIA/NIH (P30 AG072946).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All BBDP, UA-HBB, and UK-ADRC subjects provided written consent for study procedures, autopsy and sharing of de-identified data prior to enrollment. The study and its consenting procedures were approved by the Western IRB of Puyallup, Washington [BBDP], University of Auckland Human Participants Ethics Committee [UA-HBB], and University of Kentucky IRB [UK-ADRC] gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets and code are available from the corresponding author upon reasonable request.
Abbreviations:
- AD
- Alzheimer’s disease
- ApoE
- Apolipoprotein E
- ApoJ
- Apolipoprotein J
- ApoER2
- ApoE receptor 2
- CA
- Cornu ammonis
- CR
- Cajal-Retzius
- Dab1
- Disabled homolog-1
- DG
- Dentate gyrus
- ErC
- Entorhinal region
- GVD
- Granulovacuolar degeneration body
- L2
- Layer II
- LC
- Locus coeruleus
- LIMK1
- LIM domain kinase-1
- LRP8
- Low-density lipoprotein receptor-related protein 8 (gene encoding ApoER2)
- LTP
- Long-term potentiation
- NEUN
- neuronal nuclear/soma antigen
- NFL
- Neurofilament light chain
- NFT
- Neurofibrillary tangle
- NP
- Neuritic plaque
- NT
- Neuropil thread
- P85α
- PI3K regulatory subunit P85alpha
- PC
- Peri-coeruleus
- PI
- Phosphatidylinositol
- PIP2
- Phosphatidylinositol-(4,5)-bisphosphate
- PI3K
- Phosphatidylinositol-3-kinase
- PMI
- Postmortem interval
- ProS
- Prosubiculum
- PSD95
- Postsynaptic density protein 95
- pTau
- pTauSer202/Thr205
- RAAAD-P-LTP
- Reelin/ApoE/ApoJ-ApoER2-Dab1-P85-LIMK1-Tau-PSD95
- RELN
- gene encoding Reelin protein
- sAD
- sporadic AD
- SO
- Stratum oriens
- SP
- Stratum pyramidale SR Stratum radiatum
- SYNP
- Synaptophysin
